Specifically, baseline levels of sPD-1 did not associate with clinical outcomes in esophageal cancer patients receiving chemotherapy (with or without radiation or surgical resection) [63], pancreatic cancer patients treated with chemotherapy [231], metastatic clear cell renal cell carcinoma receiving bevacizumab [222], and hepatocellular carcinoma patients treated with radiotherapy [232]. This evidence concerns the gene HOXD13 and hepatocellular carcinoma.